ElpasBio Achieves Key Milestone in AlloJoin® Clinical Trials, Targeting Knee Osteoarthritis Relief

ElpasBio Completes Patient Enrollment in Phase III Clinical Trial of AlloJoin®

ElpasBio Holdings, a pioneering biotechnology firm specializing in regenerative medicine, has reached a significant milestone in its clinical research journey. As of May 2026, the company successfully wrapped up patient enrollment for its Phase III pivotal clinical trial concerning AlloJoin® (lotazadromcel). This innovative therapy utilizes allogeneic human adipose-derived mesenchymal stem cells (haMPC) that potentially offer transformative solutions for patients suffering from knee osteoarthritis (KOA).

AlloJoin® is at the forefront of regenerative medicine, developed entirely through ElpasBio’s proprietary haMPC technology platform. It aims to provide lasting symptom relief by mitigating inflammation and fostering the restoration of damaged cartilage. One of the critical goals of this clinical trial is to establish AlloJoin® as the first regenerative therapy capable of modifying the disease's progression—an aspiration that embodies hope for KOA patients around the globe.

The Clinical Trial Process and Expectations

ElpasBio’s Phase III trial marks a groundbreaking dual-primary-endpoint clinical study focused on disease modification in KOA, making it unique in the realm of regenerative medicine. The company plans to announce the trial data in 2027 and is set to file a New Drug Application (NDA) to China’s National Medical Products Administration later that same year. According to Tony (Bizuo) Liu, Chairman of ElpasBio, the efficient enrollment of over 500 patients underscores a dire need for effective treatment in this area, as current therapies offer limited improvement.

Strategic Partnerships to Enhance Commercialization

ElpasBio is also taking strategic steps toward commercialization. In January 2026, a collaboration agreement was struck with Fosun Kairos, aimed at accelerating the commercialization of AlloJoin® specifically for KOA treatment across Mainland China, along with Hong Kong SAR and Macau SAR. While ElpasBio retains full responsibilities for development, regulatory registration, and manufacturing within these territories, they will maintain all commercialization rights outside them—paving the way for future market expansion.

Understanding Knee Osteoarthritis

Knee osteoarthritis represents an age-related degenerative joint condition resulting in severe pain, stiffness, and functional limitations for affected individuals. It significantly diminishes the quality of life for millions of patients. As the population ages, particularly in regions like China where the number of osteoarthritis patients is projected to reach around 160 million by 2025, the need for novel therapies becomes increasingly urgent. Conventional treatment options often fall short, highlighting the importance of innovative approaches such as AlloJoin®.

ElpasBio: A Leader in Regenerative Medicine

Founded as a spin-off from AbelZeta Pharma, Inc. in 2023, ElpasBio is rapidly establishing itself as a leader in regenerative medicine. Their expertise, spanning over 15 years in the stem cell sector, has fostered the development of various stem cell products and significant advancements in both autologous and allogeneic therapies. The company operates compliant manufacturing and research facilities in Wuxi and Shanghai, underscoring their commitment to adhering to high standards in drug development.

ElpasBio's AlloJoin® stands out as the first stem cell drug in China to secure permission for Phase III clinical trials aimed at addressing knee osteoarthritis, an endeavor likely to revolutionize treatment protocols for this common condition.

Conclusion

As ElpasBio gears up for the next phases of its clinical trials and commercialization efforts, the landscape of KOA treatment could significantly transform, offering new hope for patients affected by this painful condition. With a robust research platform and strategic partnerships in place, ElpasBio is on the cusp of making a meaningful impact in regenerative medicine and improving patient outcomes worldwide.